Qinglin Li

Qinglin Li

Auto-generated profile, based on publicly available information

Qinglin Li

Borch Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, 720 Clinic Drive, West Lafayette, IN 47907, U.S.A

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2002 in Cell
Verified
Journal Article
Closed access
QLQing-Lin Li
Qing-Lin Li
KIKosei Ito
Kosei Ito
CSChohei Sakakura
Chohei Sakakura
HFHiroshi Fukamachi
Hiroshi Fukamachi
KIKen-Ichi Inoue
Ken-Ichi Inoue
YIYoshiaki Ito
Yoshiaki Ito

1 December 2000 in Molecular and Cellular Biology
Verified
Journal Article
Open access
PDF file
KLKyeong-Sook Lee
Kyeong-Sook Lee
HKHyun-Jung Kim
Hyun-Jung Kim
QLQing-Lin Li
Qing-Lin Li
XCXin-Zi Chi
Xin-Zi Chi
CUChisato Ueta
Chisato Ueta
SBSuk-Chul Bae
Suk-Chul Bae
When C2C12 pluripotent mesenchymal precursor cells are treated with transforming growth factor β1 (TGF-β1), terminal differentiation into myotubes is blocked. Treatment with bone morphogenetic protein 2 (BMP-2) not only blocks myogenic differentiation of C2C12 cells but also induces osteoblast differentiation. The molecular mechanisms governing the ability of TGF-β1 and BMP-2 to both induce ligand-specific responses and inhibit myogenic differentiation are not known. We identified Runx2/PEBP2αA/Cbfa1, a global regulator of osteogenesis, as a major TGF-β1-responsive element binding protein induced by TGF-β1 and BMP-2 in C2C12 cells. Consistent with the observation that Runx2 can be induced by either TGF-β1 or BMP-2, the exogenous expression of Runx2 mediated some of the effects of TGF-β1 and BMP-2 but not osteoblast-specific gene expression. Runx2 mimicked common effects of TGF-β1 and BMP-2 by inducing expression of matrix gene products (for example, collagen and fibronectin), suppressing MyoD expression, and inhibiting myotube formation of C2C12 cells. For osteoblast differentiation, an additional effector, BMP-specific Smad protein, was required. Our results indicate that Runx2 is a major target gene shared by TGF-β and BMP signaling pathways and that the coordinated action of Runx2 and BMP-activated Smads leads to the induction of osteoblast-specific gene expression in C2C12 cells.

15 June 2008 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
CLChengyu Liang
Chengyu Liang
JLJong-Soo Lee
Jong-Soo Lee
KIKyung-Soo Inn
Kyung-Soo Inn
MGMichaela U. Gack
Michaela U. Gack
QLQinglin Li
Qinglin Li
JJJae U. Jung
Jae U. Jung

18 October 2009 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
JLJong-Soo Lee
Jong-Soo Lee
QLQinglin Li
Qinglin Li
JLJune-Yong Lee
June-Yong Lee
SLSun-Hwa Lee
Sun-Hwa Lee
JJJoseph H. Jeong
Joseph H. Jeong
JJJae U. Jung
Jae U. Jung

1 September 2005 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
XCXin-Zi Chi
Xin-Zi Chi
JYJeung-Ook Yang
Jeung-Ook Yang
KLKwang-Youl Lee
Kwang-Youl Lee
KIKosei Ito
Kosei Ito
CSChohei Sakakura
Chohei Sakakura
SBSuk-Chul Bae
Suk-Chul Bae
RUNX3 has been suggested to be a tumor suppressor of gastric cancer. The gastric mucosa of the Runx3-null mouse develops hyperplasia due to enhanced proliferation and suppressed apoptosis accompanied by a decreased sensitivity to transforming growth factor beta1 (TGF-beta1). It is known that TGF-beta1 induces cell growth arrest by activating CDKN1A (p21(WAF1)(/Cip1)), which encodes a cyclin-dependent kinase inhibitor, and this signaling cascade is considered to be a tumor suppressor pathway. However, the lineage-specific transcription factor that cooperates with SMADs to induce p21 expression is not known. Here we show that RUNX3 is required for the TGF-beta-dependent induction of p21 expression in stomach epithelial cells. Overexpression of RUNX3 potentiates TGF-beta-dependent endogenous p21 induction. In cooperation with SMADs, RUNX3 synergistically activates the p21 promoter. In contrast, RUNX3-R122C, a mutation identified in a gastric cancer patient, abolished the ability to activate the p21 promoter or cooperate with SMADs. Furthermore, areas in mouse and human gastric epithelium where RUNX3 is expressed coincided with those where p21 is expressed. Our results suggest that at least part of the tumor suppressor activity of RUNX3 is associated with its ability to induce p21 expression.

31 October 2017 in Cancer Research
Verified
Journal Article
Closed access
PDF file
RFRochelle Frankson
Rochelle Frankson
ZYZhi-Hong Yu
Zhi-Hong Yu
YBYunpeng Bai
Yunpeng Bai
QLQinglin Li
Qinglin Li
RZRuo-Yu Zhang
Ruo-Yu Zhang
ZZZhong-Yin Zhang
Zhong-Yin Zhang
Protein tyrosine phosphatases (PTP) are exciting and novel targets for cancer drug discovery that work in concert with protein tyrosine kinases (PTK) in controlling cellular homeostasis. Given the activating role that some PTKs play in initiating growth factor–mediated cellular processes, PTPs are usually perceived as the negative regulators of these events and therefore tumor suppressive in nature. However, mounting evidence indicate that PTPs do not always antagonize the activity of PTKs in regulating tyrosine phosphorylation, but can also play dominant roles in the initiation and progression of signaling cascades that regulate cell functions. It follows, therefore, that PTP malfunction can actively contribute to a host of human disorders, in particular, cancer, metabolic syndromes, and autoimmune diseases. The Src homology domain containing phosphatase 2 (SHP2) and the three-membered family of phosphatases of regenerating liver (PRL) are infamously oncogenic members of the PTP superfamily. Both are established regulators of major cancer pathways such as Ras/ERK1/2, Src, JAK/STAT, JNK, NF-κB, and PTEN/PI3K/AKT. Furthermore, upregulation, mutation, or other dysregulation of these PTPs has been positively correlated with cancer initiation and progression. This review will provide topical coverage of target validation and drug discovery efforts made in targeting these oncogenic PTPs as compelling candidates for cancer therapy. Cancer Res; 77(21); 5701–5. ©2017 AACR.